Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash from Investing Activities (2019 - 2025)

Allogene Therapeutics' Cash from Investing Activities history spans 7 years, with the latest figure at $11.9 million for Q3 2025.

  • For Q3 2025, Cash from Investing Activities rose 115.71% year-over-year to $11.9 million; the TTM value through Sep 2025 reached $116.9 million, up 32.49%, while the annual FY2024 figure was $75.7 million, 53.65% down from the prior year.
  • Cash from Investing Activities for Q3 2025 was $11.9 million at Allogene Therapeutics, down from $43.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $112.9 million in Q1 2023 and bottomed at -$76.0 million in Q3 2024.
  • The 5-year median for Cash from Investing Activities is $24.9 million (2022), against an average of $30.0 million.
  • The largest annual shift saw Cash from Investing Activities surged 745.02% in 2021 before it tumbled 237.59% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at $29.2 million in 2021, then skyrocketed by 69.56% to $49.6 million in 2022, then surged by 36.02% to $67.5 million in 2023, then fell by 18.57% to $54.9 million in 2024, then plummeted by 78.27% to $11.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Cash from Investing Activities are $11.9 million (Q3 2025), $43.8 million (Q2 2025), and $6.2 million (Q1 2025).